<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fondaparinux: Dosing and adverse effects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fondaparinux: Dosing and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fondaparinux: Dosing and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth A Bauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> (Arixtra) is a synthetic anticoagulant based on the pentasaccharide sequence that makes up the minimal antithrombin (AT) binding region of heparin. Similar to low molecular weight heparins, it is an indirect inhibitor of factor Xa, but it does not inhibit thrombin at all. Fondaparinux has a longer half-life than heparin and does not interact with platelets, both of which may be advantageous in certain settings.</p><p>This topic review discusses the dosing and adverse effects of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, including dosing in patients with renal insufficiency and management of bleeding.</p><p>Indications for <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> are presented in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>Deep vein thrombosis and pulmonary embolism – (See  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial vein thrombosis – (See  <a class="medical medical_review" href="/z/d/html/8199.html" rel="external">"Superficial vein thrombosis and phlebitis of the lower extremity veins"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Thromboprophylaxis (medical patients) – (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Thromboprophylaxis (surgical patients) – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute coronary syndrome – (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Heparin-induced thrombocytopenia (HIT) – (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p></p><p>Information for other anticoagulants is also presented separately: </p><p class="bulletIndent1"><span class="glyph">●</span>Heparins – (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> and other <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonists – (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Direct oral anticoagulants – (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H1736413"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> consists of a highly sulfated pentasaccharide derived from the minimal antithrombin (AT)-binding region of heparin. It is an indirect factor Xa inhibitor (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 1</a>). It acts by binding to and inducing a conformational change in AT that increases the ability of AT to inactivate factor Xa (<a class="graphic graphic_figure graphicRef101832" href="/z/d/graphic/101832.html" rel="external">figure 2</a>) [<a href="#rid1">1,2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> binds to AT with a higher affinity (dissociation constant 50 nmol) than the native pentasaccharide of <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> or low molecular weight heparin, and it causes a conformational change in AT that significantly increases the ability of AT to inactivate factor Xa. The binding of fondaparinux to AT is stoichiometric (1:1) and reversible [<a href="#rid3">3-5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> cannot bind to or inactivate thrombin (factor IIa) because it cannot form a ternary complex with AT and thrombin (<a class="graphic graphic_figure graphicRef101832" href="/z/d/graphic/101832.html" rel="external">figure 2</a>). Ternary complex formation requires pentasaccharide-containing chains at least 18 saccharide units long, such as those present in <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> and, to a lesser extent, low molecular weight heparin preparations. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Mechanisms of action'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> does not bind to or interact with other plasma proteins or cellular elements. Specifically, fondaparinux does not interact with platelets or platelet factor 4, and thus, unlike heparin, is not expected to be capable of inducing a heparin-induced thrombocytopenia (HIT)-like syndrome [<a href="#rid6">6-11</a>]. In the major trials evaluating the use of fondaparinux for thromboprophylaxis, no cases of HIT were observed [<a href="#rid8">8</a>]. Several case series describe the effective use of fondaparinux in the setting of HIT [<a href="#rid12">12-16</a>]. However, there are rare case reports of HIT in which fondaparinux was administered [<a href="#rid17">17-20</a>]. The use of fondaparinux in HIT is described separately. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia", section on 'Pathophysiology'</a> and  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Fondaparinux'</a>.)</p><p class="headingAnchor" id="H4208184561"><span class="h2">Metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> is 100 percent bioavailable after subcutaneous injection, with half-maximal and peak serum concentrations reached in 25 minutes and 1.7 hours following subcutaneous injection, respectively [<a href="#rid21">21</a>]. The half-life of fondaparinux is 15 to 17 hours. Anticoagulant activity persists for about three to five half-lives following discontinuation of fondaparinux, or a period of two to four days in individuals with normal renal function.</p><p>The majority of an administered dose of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is cleared by the kidney and excreted unchanged in the urine. Clearance of this drug is decreased in individuals with reduced creatinine clearance, and use is not recommended in individuals with creatinine clearance &lt;30 mL/min. (See <a class="local">'Indications and contraindications'</a> below.)</p><p><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> metabolism is not affected by hepatic failure; however, patients with hepatic failure may be at increased risk of hemorrhage due to a number of hemostatic changes. (See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p class="headingAnchor" id="H1677004280"><span class="h2">Long-acting analogs</span><span class="headingEndMark"> — </span>Attempts to develop long-acting analogs of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> have not resulted in any clinically approved agents. The following drugs were evaluated in phase III trials.</p><p class="bulletIndent1"><span class="glyph">●</span>Idraparinux was a longer half-life analog of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> that could be given subcutaneously once per week. Development was halted due to an increased risk of bleeding in nonvalvular atrial fibrillation; decreased efficacy was also found in pulmonary embolism, as compared with standard therapy [<a href="#rid22">22-24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Idrabiotaparinux (SSR 126517) is a biotinylated version of idraparinux that could be neutralized by intravenous infusion of avidin, which binds <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a> [<a href="#rid25">25-27</a>].</p><p></p><p class="headingAnchor" id="H3065436885"><span class="h2">Advantages and disadvantages compared with other anticoagulants</span><span class="headingEndMark"> — </span>The choice of anticoagulant should be based on evidence for the given clinical setting. In settings in which <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is considered clinically equivalent with other anticoagulants, the following advantages and disadvantages may be worth considering:</p><p class="bulletIndent1"><span class="glyph">●</span>Advantages</p><p class="bulletIndent2"><span class="glyph">•</span>Longer half-life allows once daily dosing</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of platelet interaction makes risk of HIT negligible</p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring not required with routine use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disadvantages</p><p class="bulletIndent2"><span class="glyph">•</span>Must be given parenterally</p><p class="bulletIndent2"><span class="glyph">•</span>No approved antidote or reversal agent (although <a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">andexanet alfa</a> may be used) (See <a class="local">'Bleeding/emergency surgery'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Inability to monitor at most centers due to lack of availability of fondaparinux-calibrated anti-factor Xa levels</p><p></p><p class="headingAnchor" id="H1579490054"><span class="h1">INDICATIONS AND CONTRAINDICATIONS</span></p><p><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> can be used for prophylaxis and treatment of venous thromboembolism (VTE) in a number of medical and perioperative settings. Evidence for its efficacy and comparison with other anticoagulants is discussed in separate topic reviews on the specific clinical setting:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical patients</strong> – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical patients</strong> – (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with VTE</strong> – (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a> and  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a> and  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with superficial vein thrombosis</strong> – (See  <a class="medical medical_review" href="/z/d/html/8199.html" rel="external">"Superficial vein thrombosis and phlebitis of the lower extremity veins"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with acute coronary syndromes</strong> – (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with heparin-induced thrombocytopenia (HIT)</strong> – (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p></p><p>We generally avoid using <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in the following patient groups:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnant women, unless there is a contraindication to heparin (see <a class="local">'Pregnancy'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with a creatinine clearance &lt;30 mL/min</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals weighing &lt;50 kg in the prophylactic setting (dose reduction is used in the therapeutic setting for individuals &lt;50 kg)</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with bacterial endocarditis or other relative or absolute contraindication for an anticoagulant</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals undergoing neurosurgery or spine surgery</p><p></p><p>Additional possible contraindications that apply to the use of anticoagulants in general are listed in the table (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 1</a>); this is not intended to substitute for the judgement of the treating clinician who can weigh the risks and benefits for the individual patient.</p><p>A lower dose of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> typically is used in patients weighing &lt;50 kg receiving fondaparinux for VTE therapy. (See <a class="local">'Dosing'</a> below.)</p><p>Therapy is individualized for those with thrombocytopenia depending on the reason for thrombocytopenia and the estimated bleeding risk. As an example, we may avoid using <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in individuals with a platelet count &lt;70,000/microL due to bone marrow suppression; however, if thrombocytopenia is due to HIT and the platelet count is expected to rise, it may be appropriate to give fondaparinux since the major concern is thrombosis rather than bleeding.</p><p class="headingAnchor" id="H6"><span class="h1">DOSING</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> is given subcutaneously once daily. The dose in individuals with normal renal function is based on body weight and the indication for anticoagulant use (eg, prophylaxis for venous thromboembolism [VTE] versus therapy) [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE prophylaxis or acute coronary syndromes</strong> – 2.5 mg once daily. In the perioperative setting, the first dose is given six to eight hours postoperatively (after skin closure) as was done in all of the major clinical trials. A 1.5 mg dose is available for orthopedic VTE prophylaxis in Europe, but not in the United States. The 1.5 mg dose is suggested for individuals with creatinine clearance of 20 to 50 mL/min, although safety and efficacy of this dose has not been well-studied. (See <a class="local">'Elective surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superficial vein thrombosis (treatment)</strong> – 2.5 mg once daily. Duration of therapy and other interventions are presented separately. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE (treatment)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients weighing &lt;50 kg – 5 mg once daily</p><p class="bulletIndent2"><span class="glyph">•</span>Patients weighing 50 to 100 kg – 7.5 mg once daily</p><p class="bulletIndent2"><span class="glyph">•</span>Patients weighing &gt;100 kg – 10 mg once daily</p><p></p><p>The duration of therapy is discussed in topic reviews on the specific indications. (See <a class="local">'Indications and contraindications'</a> above.)</p><p><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> cannot be given intramuscularly.</p><p class="headingAnchor" id="H4004533291"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> does not require monitoring in routine clinical use. Monitoring of drug levels or coagulation testing was not performed in clinical trials. However, when therapeutic dosing is used in individuals at extremes of body weight, dose adjustments may be appropriate and drug levels may be obtained.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug levels</strong> – In cases where <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is required and levels can be obtained in a timely fashion (eg, extremes of very high or very low body weight), anti-factor Xa activity can be measured approximately three hours after the dose is administered. The anti-factor Xa activity assay must be calibrated using fondaparinux as a reference standard. Results are presented as fondaparinux levels in mcg/mL. The therapeutic range has not been established, but typical levels are in the range of 0.39 to 0.5 mcg/mL for prophylactic-dose fondaparinux and 0.5 to 1.5 mcg/mL for therapeutic-dose fondaparinux. Communication with the testing laboratory is advised.</p><p></p><p class="bulletIndent1">The activated partial thromboplastin time (aPTT) cannot be used to monitor <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, although it may become prolonged at therapeutic doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal function</strong> – Renal function should be assessed before starting <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> because patients with impaired renal function may require a dose adjustment (or use of a different anticoagulant if renal insufficiency is severe). In patients taking fondaparinux for an extended period of time (eg, many months to years), renal function should be monitored periodically and the drug discontinued if the creatinine clearance decreases to &lt;30 mL/min or shows a trend toward worsening.</p><p></p><p class="bulletIndent1">For individuals with stable renal insufficiency and a creatinine clearance between 30 and 50 mL/minute, it may be appropriate to switch to low molecular weight heparin or <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>, unless levels are available in a timely fashion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet count</strong> – Routine platelet count monitoring is not required with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> administration, given the negligible risk for the development of heparin-induced thrombocytopenia (HIT) [<a href="#rid29">29</a>]. However, patients at risk of developing thrombocytopenia for other reasons should undergo periodic monitoring of the platelet count.</p><p></p><p class="headingAnchor" id="H1601990015"><span class="h1">TRANSITIONING BETWEEN ANTICOAGULANTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>From other anticoagulants to </strong><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> – The onset of action of fondaparinux is rapid, so it is generally started at the time another anticoagulant is discontinued. For patients on <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, it is generally started when the international normalized ratio (INR) drops below 2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>From </strong><strong>fondaparinux</strong><strong> to other agents</strong> – For patients receiving <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> who will be transitioned to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in the setting of acute venous thromboembolism, we typically start warfarin and fondaparinux at the same time and continue fondaparinux for at least five days until the INR is in the therapeutic range. For patients receiving fondaparinux who will be transitioned to a direct acting oral anticoagulant (DOAC; eg, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>), we typically start the DOAC 24 hours after the last dose of fondaparinux.</p><p></p><p class="headingAnchor" id="H900871597"><span class="h1">USE IN SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3648076479"><span class="h2">Extremes of weight</span><span class="headingEndMark"> — </span>In the prophylactic setting, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is avoided for patients weighing &lt;50 kg; dosing of fondaparinux for patients ≥50 kg is not generally adjusted for weight.</p><p>In the therapeutic setting, dosing of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is based on weight, as discussed above. (See <a class="local">'Dosing'</a> above.)</p><p class="headingAnchor" id="H3264468542"><span class="h2">Renal insufficiency</span><span class="headingEndMark"> — </span>As noted above, we do not use <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> for individuals with creatinine clearance &lt;30 mL/min. Clinical trials of fondaparinux excluded individuals with creatinine clearance &lt;30 mL/min or serum creatinine &gt;1.8 mg/dL [<a href="#rid30">30</a>].</p><p>For individuals with creatinine clearance between 30 and 50 mL/minute, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> may be used with caution. This decision, along with the specific dose and potential use of anti-factor Xa monitoring in this setting, is individualized. (See <a class="local">'Monitoring'</a> above.)</p><p><a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">Unfractionated heparin</a> may be a better alternative in some patients with renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Unfractionated heparin'</a>.)</p><p class="headingAnchor" id="H911896319"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in individuals over the age of 75 years appears to be safe, provided that the patient weighs &gt;50 kg and has normal renal function. </p><p class="headingAnchor" id="H488749887"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Clinical experience with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in pregnancy is less than that with low molecular weight (LMW) heparin, but use in pregnancy has been reported. Potential concerns include its longer half-life than LMW heparin and the possibility of underdosing as pregnancy weight increases; there is also concern regarding potential passage of drug across the placenta to the fetus. </p><p>We limit the use of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in pregnancy to individuals who require an anticoagulant but are unable to tolerate heparin (due to severe hypersensitivity reactions or heparin-induced thrombocytopenia [HIT]). Anticoagulation during pregnancy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H299196713"><span class="h2">Children</span><span class="headingEndMark"> — </span>Clinical experience with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in children is extremely limited [<a href="#rid31">31,32</a>]. Its use is generally limited to children with HIT who require cessation of heparin and ongoing anticoagulation with a non-heparinoid agent other than <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a>. (See  <a class="medical medical_review" href="/z/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"</a>.)</p><p class="headingAnchor" id="H756863694"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H2933616006"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> increases the risk of bleeding, similar to other anticoagulants. Bleeding risk may be increased in those with underlying impairment of platelet function or coagulation (eg, liver disease, decreased kidney function, concomitant use of nonsteroidal antiinflammatory drugs [NSAIDs]). Bleeding risk with fondaparinux may be of greater concern than with other anticoagulants because fondaparinux lacks an approved antidote or reversal agent, although <a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">andexanet alfa</a> may be used. (See <a class="local">'Bleeding/emergency surgery'</a> below.)</p><p>Several randomized trials comparing <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> or low molecular weight (LMW) heparin have documented comparable bleeding rates, typically on the order of 1 to 2 percent for major bleeding and 6 to 8 percent for clinically relevant non-major bleeding [<a href="#rid21">21,30,33-38</a>].</p><p>Initial studies using higher prophylactic doses in the orthopedic setting found a higher rate of major bleeding [<a href="#rid3">3</a>]. Bleeding risk in the perioperative setting was also greater if <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> was started sooner than six hours after skin closure [<a href="#rid39">39</a>]. A review of data from several large randomized trials also noted increased risk of major bleeding in patients who were older, male, and had body weight &lt;50 kg and impaired kidney function [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H650797118"><span class="h2">Spinal/epidural hematoma</span><span class="headingEndMark"> — </span>Like other anticoagulants, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> product labeling includes a Boxed Warning regarding the risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or undergoing spinal puncture [<a href="#rid28">28</a>]. The risk is increased in those with indwelling epidural catheters, other drugs that impair hemostasis (eg, anti-platelet agents), traumatic or repeated epidural or spinal puncture, or a history of spinal surgery. According to the manufacturer, no spinal or epidural hematomas were reported when fondaparinux was withheld until at least two hours after removal of epidural catheters. An epidural hematoma has been reported related to multiple attempts at placing an epidural catheter.</p><p class="headingAnchor" id="H4009381027"><span class="h2">Effect on coagulation testing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> at prophylactic doses (eg, 2.5 mg once daily) does not appreciably prolong the prothrombin time (PT) or activated partial thromboplastin time (aPTT) [<a href="#rid41">41,42</a>]; the aPTT may become prolonged at higher doses. There is no effect on the thrombin time, platelet function, or fibrinolysis.</p><p><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> does have anti-factor Xa activity; in the rare cases when anti-factor Xa activity is used for monitoring, the assay should be calibrated for fondaparinux. (See <a class="local">'Monitoring'</a> above.)</p><p class="headingAnchor" id="H831144"><span class="h1">MANAGEMENT AND PREVENTION OF BLEEDING</span></p><p class="headingAnchor" id="H3331234277"><span class="h2">Bleeding/emergency surgery</span><span class="headingEndMark"> — </span>There are very few data to guide the management of bleeding or emergency surgery in patients anticoagulated with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>. Most clinical data come from studies in healthy volunteers; there are no high-quality data to show that available hemostatic therapies improve outcomes in patients with bleeding on fondaparinux [<a href="#rid43">43</a>]. Our approach is based largely on preclinical or indirect data and an understanding of the mechanisms of action of the drug.</p><p><a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">Andexanet alfa</a>, a catalytically inactive form of factor Xa, is able to sequester direct factor Xa inhibitors and is likely to be effective for reversing indirect-acting factor Xa inhibitors such as <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> [<a href="#rid44">44,45</a>]. Andexanet was approved by the US Food and Drug Administration (FDA) in May of 2018 for the reversal of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Factor Xa inhibitors'</a>.)</p><p>We individualize the management of bleeding, taking into account clinical variables for each patient and balancing the risks of bleeding complications with the risks of thrombosis from drug discontinuation, andexanet, or prohemostatic therapies. For those for whom a reversal agent is deemed to be necessary, andexanet is a good option because it will specifically neutralize the anticoagulant activity of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>. However, clinicians should be aware that andexanet has only gained FDA approval for the reversal of the oral direct factor Xa inhibitors <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, and the dose of andexanet for the reversal of fondaparinux has not been established. </p><p>Activated prothrombin complex concentrates (aPCC; eg, factor eight inhibitor bypassing agent [FEIBA]), or recombinant activated factor VII (rFVIIa) may provide some reversal of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> activity, although clinical data are limited to studies using in vitro coagulation testing rather than management of patients with bleeding [<a href="#rid46">46,47</a>]. In the one study that compared aPCC and rFVIIa using coagulation testing in non-bleeding volunteers, aPCC was better able to normalize thrombin generation time than rFVIIa [<a href="#rid47">47</a>]. The agents carry risks of thrombosis that must be balanced with the risks of bleeding for each patient. (See  <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'PCCs'</a>.)</p><p>Measurement of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> drug levels using an anti-factor Xa assay calibrated to fondaparinux is appropriate in patients with major bleeding; however, this test is not widely available. Fondaparinux may be dialyzable [<a href="#rid46">46</a>].</p><p>Additional general measures that should be taken in any patient with anticoagulant-associated severe bleeding are presented separately. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Major bleeding'</a>.)</p><p>Evidence supporting a role for these agents includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>aPCC</strong> – In an animal model, aPCC was able to correct endogenous thrombin potential and lessen the duration of bleeding [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>rFVIIa</strong> – High doses of recombinant factor VIIa (90 mcg/kg) were shown to partially normalize the prolonged aPTT, the endogenous thrombin potential, and prothrombin activation in vivo (as measured by prothrombin fragment F1+2 levels) in healthy volunteers given therapeutic doses of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> [<a href="#rid41">41,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects"</a>.)</p><p></p><p>In contrast to the therapies discussed above (<a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">andexanet alfa</a>, aPCC, rFVIIa), <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">protamine sulfate</a> is not effective in reversing <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>. <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> has no role in fondaparinux reversal.</p><p class="headingAnchor" id="H495387621"><span class="h2">Elective surgery</span><span class="headingEndMark"> — </span>Anticoagulant activity of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> persists for about three to five half-lives following discontinuation, or a period of two to four days in individuals with normal renal function.</p><p>Thus, major elective surgery requiring anticoagulant discontinuation should be delayed until two to four days after the last <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> dose. For certain low bleeding risk procedures, 24 hours may be sufficient. These time frames should be extended for individuals with renal insufficiency due to reduced drug clearance. Information regarding the bleeding risk of various procedures, the need for anticoagulant discontinuation, and the need for perioperative bridging anticoagulation is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p>For individuals receiving postoperative thromboprophylaxis, the major clinical trials administered the first postoperative dose six to eight hours after skin closure. </p><p>Providing the first postoperative dose on the morning after orthopedic surgery appears to be an acceptable alternative, as was demonstrated in the Flexibility in Administration of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> for Prevention of Symptomatic Venous Thromboembolism in Orthopedic Surgery (FLEXTRA) trial [<a href="#rid50">50</a>]. Over 2000 patients were randomly assigned to receive the first dose of fondaparinux either six to eight hours after surgery or on the morning after surgery; at six weeks, the incidences of symptomatic venous thromboembolism and major bleeding were similar with either schedule (1.9 versus 1.8 percent and 1.2 versus 0.7 percent, respectively).</p><p class="headingAnchor" id="H112801773"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action and metabolism</strong> – <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> is a synthetic anticoagulant based on the pentasaccharide sequence present in heparin and low molecular weight (LMW) heparin. It acts as an indirect inhibitor of factor Xa (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 1</a>); it does not inhibit thrombin (<a class="graphic graphic_figure graphicRef101832" href="/z/d/graphic/101832.html" rel="external">figure 2</a>). It is metabolized by the kidneys and has a half-life of approximately 15 to 17 hours. (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Indications are discussed in topic reviews listed above. We do not use <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in children, individuals with creatinine clearance &lt;30 mL/min, or individuals weighing &lt;50 kg (for venous thromboembolism [VTE] prophylaxis). We generally avoid fondaparinux in pregnancy, unless heparin cannot be used. (See <a class="local">'Indications and contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose </strong>– Typical dosing (subcutaneous, once daily) (see <a class="local">'Dosing'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>VTE prophylaxis or acute coronary syndrome</strong> – 2.5 mg </p><p class="bulletIndent2"><span class="glyph">•</span><strong>VTE treatment (weight-based)</strong> – 5, 7.5, or 10 mg for body weight &lt;50 kg, 50 to 100 kg, or &gt;100 kg </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– Routine monitoring generally is not required. If needed, anti-factor Xa levels can be used, provided the assay is calibrated for <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>. Kidney function should be checked periodically during prolonged fondaparinux use. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks</strong> – Like other anticoagulants, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> increases the risk of bleeding; there is a Boxed Warning regarding risk of spinal/epidural hematoma. Bleeding risk was comparable to LMW heparin in VTE prophylaxis trials. Fondaparinux typically does not prolong the prothrombin time (PT) or activated partial thromboplastin time (aPTT) at the 2.5 mg per day dose, but the aPTT may become prolonged at higher doses. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleed management</strong> – For patients with major or life-threatening bleeding, the decision to use a prohemostatic agent is individualized based on bleed severity or bleeding risk in emergency surgery. Options include <a class="drug drug_general" data-topicid="8434" href="/z/d/drug information/8434.html" rel="external">activated prothrombin complex concentrate</a> (aPCC; factor eight inhibitor bypassing agent [FEIBA]), recombinant activated factor VII (rFVIIa), or the reversal agent <a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">andexanet alfa</a>. There are little data on these agents with fondaparinux-associated bleeding. Activated clotting factors and reversal of anticoagulation also carry a thrombotic risk and should not be used for minor bleeding or bleeding that can be controlled by other means. (See <a class="local">'Bleeding/emergency surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative </strong>– For elective surgery, we generally discontinue <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> two to four days before the procedure. Postoperative thromboprophylaxis is generally initiated six to eight hours after skin closure, although giving the first dose the morning after surgery is also reasonable. (See <a class="local">'Elective surgery'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nijkeuter M, Huisman MV. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Curr Opin Pulm Med 2004; 10:338.</a></li><li><a class="nounderline abstract_t">Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res 2012; 129:407.</a></li><li><a class="nounderline abstract_t">Turpie AG, Gallus AS, Hoek JA, Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344:619.</a></li><li><a class="nounderline abstract_t">Olson ST, Björk I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267:12528.</a></li><li><a class="nounderline abstract_t">Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87:831.</a></li><li><a class="nounderline abstract_t">Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001; 58 Suppl 2:S14.</a></li><li><a class="nounderline abstract_t">Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Hematol 2002; 9:422.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106:3791.</a></li><li><a class="nounderline abstract_t">Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74:1384.</a></li><li><a class="nounderline abstract_t">Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8:114.</a></li><li><a class="nounderline abstract_t">Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105:139.</a></li><li><a class="nounderline abstract_t">Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88:ECR32.</a></li><li><a class="nounderline abstract_t">D'Amico EA, Villaça PR, Gualandro SF, et al. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1:2452.</a></li><li><a class="nounderline abstract_t">Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89:1017.</a></li><li><a class="nounderline abstract_t">Kuo KH, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93:999.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011; 9:2389.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356:2653.</a></li><li><a class="nounderline abstract_t">Elalamy I, Tribout B. Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal. J Thromb Haemost 2008; 6:1242.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008; 6:1243.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thromb Haemost 2012; 108:394.</a></li><li><a class="nounderline abstract_t">Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715.</a></li><li><a class="nounderline abstract_t">van Gogh Investigators, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357:1094.</a></li><li><a class="nounderline abstract_t">van Gogh Investigators, Buller HR, Cohen AT, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357:1105.</a></li><li><a class="nounderline abstract_t">Amadeus Investigators, Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371:315.</a></li><li><a class="nounderline abstract_t">Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8:722.</a></li><li><a class="nounderline abstract_t">Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011; 9:92.</a></li><li><a class="nounderline abstract_t">Büller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379:123.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021345s032lbl.pdf.</li><li><a class="nounderline abstract_t">Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S.</a></li><li><a class="nounderline abstract_t">Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833.</a></li><li><a class="nounderline abstract_t">Young G, Yee DL, O'Brien SH, et al. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer 2011; 57:1049.</a></li><li><a class="nounderline abstract_t">Ko RH, Michieli C, Lira JL, Young G. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res 2014; 134:643.</a></li><li><a class="nounderline abstract_t">Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695.</a></li><li><a class="nounderline abstract_t">Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867.</a></li><li><a class="nounderline abstract_t">Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359:1721.</a></li><li><a class="nounderline abstract_t">Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305.</a></li><li><a class="nounderline abstract_t">Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298.</a></li><li><a class="nounderline abstract_t">Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92:1212.</a></li><li><a class="nounderline abstract_t">Turpie A, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90:364.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120:2006.</a></li><li><a class="nounderline abstract_t">Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550.</a></li><li><a class="nounderline abstract_t">Smogorzewska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130:1605.</a></li><li><a class="nounderline abstract_t">Elmer J, Wittels KA. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfus Med 2012; 22:108.</a></li><li><a class="nounderline abstract_t">Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373:2413.</a></li><li><a class="nounderline abstract_t">Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19:446.</a></li><li><a class="nounderline abstract_t">Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24:6.</a></li><li><a class="nounderline abstract_t">Desmurs-Clavel H, Huchon C, Chatard B, et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123:796.</a></li><li><a class="nounderline abstract_t">Corbonnois G, Martin M, Hacquard M, et al. Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats. Thromb Haemost 2013; 109:560.</a></li><li><a class="nounderline abstract_t">Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124:653.</a></li><li><a class="nounderline abstract_t">Colwell CW Jr, Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21:36.</a></li></ol></div><div id="topicVersionRevision">Topic 1319 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316429" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133273" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fondaparinux - data on efficacy and safety in special situations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11228275" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1618758" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038785" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11715834" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fondaparinux sodium: a selective inhibitor of factor Xa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12172461" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Heparin pentasaccharide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16109780" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607131" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518042" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388575" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607764" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14629485" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339691" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of heparin-induced thrombocytopenia with fondaparinux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886823" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883878" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582083" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Heparin-induced thrombocytopenia associated with fondaparinux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19330935" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22627967" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049858" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855670" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Idraparinux versus standard therapy for venous thromboembolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855671" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Extended prophylaxis of venous thromboembolism with idraparinux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18294998" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20088937" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946157" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22130488" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22130488" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574270" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196081" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21319285" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25087891" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585937" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172900" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049860" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794149" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794148" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175516" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12888887" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884469" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427650" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17076521" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22171588" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26559317" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23455714" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26714677" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23306598" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871253" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446183" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
